Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise
Monte Rosa Therapeutics' Chief Scientific Officer, Sharon Townson, reported an exercise-and-sell transaction involving company stock. She exercised options for 6,000 shares at $6.14 each and subsequently sold all 6,000 shares, including 400 at $24.13 and the remainder at a weighted average price of $23.2495. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan, leaving her with 67,845 directly held shares.
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 By Investing.com
Sharon Townson, Chief Scientific Officer at Monte Rosa Therapeutics, sold 6,000 shares of common stock for approximately $139,849 after exercising stock options. The sale occurred when the stock was near its 52-week high, and an InvestingPro analysis suggests the shares are overvalued. Monte Rosa Therapeutics recently presented positive preclinical data for a cancer drug candidate and Guggenheim raised its price target for the company.
Form 4 Monte Rosa Therapeutics Inc For: 7 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Monte Rosa Therapeutics Inc. for July 7th. It briefly mentions the document and offers options to view comments, but provides no further details about the filing's content. The rest of the page consists of general financial market data, popular news headlines, and navigational links related to Investing.com.
Form 4 Monte Rosa Therapeutics Inc For: 6 July By Investing.com
This article announces the filing of a Form 4 for Monte Rosa Therapeutics Inc. on July 6th. Form 4 filings typically disclose changes in beneficial ownership of a company's securities by insiders. The brief content provides the headline and mentions Monte Rosa Therapeutics Inc.
NEA adjusts Monte Rosa Therapeutics (GLUE) stake with share distribution and sales
New Enterprise Associates (NEA) has updated its ownership in Monte Rosa Therapeutics (GLUE) through a Schedule 13D/A filing. NEA 17, a part of NEA, now holds 6,692,298 shares, representing 7.9% of Monte Rosa's outstanding common stock. This adjustment includes a pro rata distribution of 1,000,000 shares to NEA 17's partners, and subsequent sales of indirectly received shares by certain NEA executives.
NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE)
NEA-affiliated funds restructured their holdings in Monte Rosa Therapeutics (NASDAQ: GLUE) through a series of internal distributions, not open-market transactions. New Enterprise Associates 17, L.P. distributed 1,000,000 shares pro rata to its partners, and NEA Partners 17 subsequently received and distributed 15,000 shares, all for no cash consideration. Director Ali Behbahani disclaims beneficial ownership for shares in which he has no pecuniary interest, indicating these were reallocations among NEA entities rather than market trades.
GLUE - Monte Rosa Therapeutics Inc Volatility & Greeks
This article provides detailed financial and performance data for Monte Rosa Therapeutics Inc. (GLUE), including its volatility, options Greeks, market capitalization, earnings per share, sales figures, and insider ownership statistics. It also highlights the stock's price performance over various periods, showing significant gains over the last year and three years.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages
Nine brokerages have given Monte Rosa Therapeutics (NASDAQ:GLUE) an average recommendation of "Moderate Buy," with an average 12-month price target of $33.33. Recent analyst target adjustments have been mixed, with some increases and some decreases. Despite recent insider selling totaling over 81,000 shares, institutional investors own nearly 80% of the stock, which recently traded near its 52-week high.
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics, Inc. announced inducement equity awards to three new non-executive employees in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include non-qualified stock options for 18,025 shares and restricted stock units for 3,900 shares, both vesting over several years. These grants are part of the Monte Rosa Therapeutics, Inc. 2026 Inducement Plan and aim to attract and retain talent.
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced the grant of inducement equity awards to three new non-executive employees. These awards, consisting of non-qualified stock options and restricted stock units, were a material inducement for their employment and comply with Nasdaq Listing Rule 5635(c)(4). The grants were approved by the compensation committee of the board of directors and were made outside of stockholder-approved equity incentive plans under the Monte Rosa Therapeutics, Inc. 2026 Inducement Plan.
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics, Inc. announced the grant of inducement equity awards to three new non-executive employees. These awards, consisting of non-qualified stock options and restricted stock units, were a material inducement for their employment and were granted outside of stockholder-approved plans in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are part of the Monte Rosa Therapeutics, Inc. 2026 Inducement Plan and were approved by the compensation committee.
Monte Rosa lures 3 new hires with stock awards worth 18,025 options
Monte Rosa Therapeutics (Nasdaq: GLUE) has granted inducement equity awards to three new non-executive employees under its 2026 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). These awards include options for 18,025 shares at an exercise price of $24.02 and 3,900 restricted stock units, both with multi-year vesting schedules. The grants serve as a material inducement for the employees to join the company, reflecting a common strategy for attracting talent in the biotechnology sector.
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics, Inc. announced the grant of inducement equity awards to three new non-executive employees. These awards, consisting of non-qualified stock options for 18,025 shares and restricted stock units for 3,900 shares, were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. The awards will vest over several years, subject to continued service.
Monte Rosa CMO Filip Janku sells $132k in company stock
Monte Rosa Therapeutics CMO Filip Janku sold 5,407 shares of company stock for $132,471 under a pre-arranged trading plan, while simultaneously acquiring the same number of shares by exercising stock options. The sale occurred near the stock's 52-week high after a 425% gain in the past year, and the company has recently seen positive analyst ratings and promising preclinical data for its drug candidates.
Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock
Filip Janku, an insider at Monte Rosa Therapeutics (NASDAQ:GLUE), sold 5,407 shares of the company's stock for approximately $132,472, reducing his ownership by 8.19%. This sale, along with several others in June, occurred as GLUE shares traded near their 52-week high, despite the company reporting wider-than-expected losses and weaker revenue. Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $33.33, though some firms hold bearish views.
Monte Rosa Therapeutics (NASDAQ: GLUE) CMO trades 5,407 shares under 10b5-1 plan
Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, exercised stock options for 5,407 shares at $13.41 per share and subsequently sold them at $24.50 per share on June 30, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on March 4, 2026. Following these trades, Janku directly owns 60,612 shares of the company.
Form 4 Monte Rosa Therapeutics Inc For: 30 June By Investing.com
This article reports on the filing of Form 4 by Monte Rosa Therapeutics Inc. for the period ending June 30. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders when they trade their company's stock. The article mentions the stock symbol GLUE, indicating a direct connection to Monte Rosa Therapeutics.
Monte Rosa Therapeutics Price Target Raised to $35.00/Share From $30.00 by Guggenheim
Guggenheim has increased its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) from $30.00 to $35.00 per share. This adjustment suggests a positive outlook on the company's future performance. However, the report does not provide details on the reasons behind the target raise.
Form 4 Monte Rosa Therapeutics Inc For: 30 June By Investing.com
This article reports on a Form 4 filing for Monte Rosa Therapeutics Inc. for the period ending June 30th. It states that the information is provided by Investing.com, a financial markets website. The core content is simply a headline about the filing.
Form 144 Monte Rosa Therapeutics For: 30 June By Investing.com
Investing.com has published a Form 144 filing for Monte Rosa Therapeutics as of June 30th. This brief article primarily lists market data for various indices, commodities, bonds, and shares, along with trending stocks and popular news articles from Investing.com. The information seems to be a standard financial markets update.
Monte Rosa (NASDAQ: GLUE) CMO exercises options, sells 6,000 shares
Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, executed an exercise-and-sell transaction, acquiring 6,000 shares at $7.56 per share through stock options and simultaneously selling them at $22.95 per share. These transactions, totaling $137,700 from the sale, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026. Following these actions, Janku directly holds 59,992 shares and retains 60,000 fully vested stock options.
Monte Rosa (NASDAQ: GLUE) director exercises options, sells 10,000 shares at $23.11
Monte Rosa Therapeutics director Anthony M. Manning exercised stock options to acquire 10,000 shares of common stock at $4.16 per share, then immediately sold all 10,000 shares at $23.11 per share in an open-market transaction. Following these transactions, Manning holds 0 direct common stock shares but retains a stock option position for 2,100 shares expiring in 2034. This insider activity was reported in a Form 4 filing.
Monte Rosa Therapeutics (GLUE) Joins Russell Growth Indexes, Is The Upside Already Priced In?
Monte Rosa Therapeutics (GLUE) has been added to several Russell growth indexes following strong recent stock performance, including a 429.93% return over one year. The company is currently unprofitable and trades at a high price-to-sales (P/S) ratio of 47x, significantly above its peers, suggesting it may be overvalued based on current financials. However, a discounted cash flow (DCF) model from Simply Wall St indicates potential undervaluation, valuing the stock at $105.46 per share against its current price of $23.90.
GLUE (NASDAQ: GLUE) option exercise; insider 10b5-1 sales total 41,845 shares
Monte Rosa Therapeutics (NASDAQ: GLUE) insider filed a Form 144, disclosing the exercise of 6,000 stock options and subsequent 10b5-1 sales totaling 41,845 shares. These sales, executed on June 23 and June 24, 2026, generated total proceeds of $882,203.50. This routine transaction is deemed neutral, indicating liquidity management rather than an unscheduled disposition.
Does Monte Rosa Therapeutics' (GLUE) Shift Into Russell Growth Indices Recast Its Biotech Risk Profile?
Monte Rosa Therapeutics (GLUE) has been reclassified from Russell Value to Russell Growth indices, including the Russell 2000 Growth, 2500 Growth, and 3000 Growth. This change primarily affects passive investors and doesn't alter the biotech's fundamental risk profile, which remains tied to its early-stage development, potential losses, and reliance on external funding. The company's investment narrative still hinges on clinical readouts, big pharma partnerships, and efficient use of its recent US$300 million equity offering.
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index
Monte Rosa Therapeutics, Inc. (NasdaqGS:GLUE) has been dropped from the Russell Microcap Value Benchmark Index. This decision coincides with several other index changes for the company on the same day, including being added to the Russell 2500 Growth, Russell Microcap Growth, and Russell 2000 Growth benchmarks, among others. The article also provides a brief company profile, financial data, analyst ratings, and recent news related to Monte Rosa Therapeutics.
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index
Monte Rosa Therapeutics, Inc. (NasdaqGS:GLUE) has been added to the Russell Microcap Growth Benchmark Index, as reported on June 29, 2026, by S&P Capital IQ. This inclusion highlights the company's growth profile within the microcap market. Simultaneously, Monte Rosa Therapeutics was dropped from the Russell Microcap Value Benchmark Index and the Russell 2000 Value Benchmark, indicating a shift in its classification toward growth-focused indices.
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark
Monte Rosa Therapeutics, Inc. (NasdaqGS:GLUE) has been removed from the Russell 2000 Value Benchmark. This update follows a series of recent changes to its benchmark inclusions and exclusions, including additions to several Russell Growth benchmarks and removals from other Russell Value benchmarks. Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing novel molecular glue degraders.
Does Monte Rosa Therapeutics' (GLUE) Shift Into Russell Growth Indices Recast Its Biotech Risk Profile?
Monte Rosa Therapeutics (GLUE) has been reclassified from Russell Value to Russell Growth indices, indicating a change in how index providers categorize the small-cap biotech company. This shift primarily affects passive investment strategies rather than the company's fundamentals or immediate risk profile. The article emphasizes that Monte Rosa Therapeutics remains a high-science, early-stage, loss-making biotech reliant on external funding and clinical readouts, with continuing concerns about losses, rich sales multiples, past dilution, and insider selling.
Monte Rosa Therapeutics, Inc. Actuals & Estimates (NASDAQ:GLUE)
This article provides comprehensive financial data and analyst estimates for Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), including its current stock price, historical performance, forecast, and upcoming earnings report. It highlights key financial metrics such as net income, revenue, and market capitalization, along with frequently asked questions about the company's stock.
Monte Rosa (GLUE) CMO sells 41,845 shares after exercising options
Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, exercised options for 36,000 shares and subsequently sold a total of 41,845 shares of GLUE stock in open-market transactions on June 23-24, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026. Following these trades, Janku directly holds 59,992 shares of Monte Rosa common stock.
GLUE Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Monte Rosa Therapeutics, Inc. (GLUE) stock, based on analyst opinions. It details the current stock price, historical performance, earnings, revenue, market capitalization, and volatility, along with an outlook for future price movements. The consensus among 6 analysts suggests a maximum price target of $37.00 and a minimum of $29.00.
Monte Rosa (GLUE) CSO sells 3,000 shares after exercising options
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson exercised options for 3,000 shares of common stock at $6.14 per share and subsequently sold those 3,000 shares for $20.00 each on June 23, 2026. These transactions, conducted under a pre-arranged Rule 10b5-1 trading plan, resulted in a net sale for Townson, leaving her with 67,845 direct shares and 203,290 exercisable stock options. The total value of the shares sold was $60,000.
Insider exercises 30,000 shares; sells 11,845 under 10b5-1 (GLUE)
An insider related to Monte Rosa Therapeutics (GLUE) exercised options for 30,000 shares and completed a pre-arranged 10b5-1 sale of 11,845 shares for $239,522.50. These transactions were reported via a Form 144 SEC filing. The filing outlines the exercise of stock options made in cash and the details of the scheduled sale.
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $29
Wells Fargo has reiterated its Buy rating for Monte Rosa Therapeutics (GLUE.US), setting a target price of $29. This indicates ongoing confidence in the company's financial prospects and stock performance.
Form 144 MONTE ROSA THERAPEUTICS INC For: 23 June By Investing.com
This article reports on a Form 144 filing for MONTE ROSA THERAPEUTICS INC as of June 23. It briefly mentions the company and its stock ticker GLUE, along with various financial market data and trending stock information.
Monte Rosa Therapeutics Inc (GLUE) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Monte Rosa Therapeutics Inc (GLUE), highlighting its current valuation score of 9.10, ranking 52 out of 389 in the Biotechnology & Medical Research industry. The company's P/E ratio is noted as -13.98, significantly below its recent high. Other key financial metrics like P/B, P/S, and P/CF are not yet disclosed.
Form 144 MONTE ROSA THERAPEUTICS For: 23 June By Investing.com
This article from Investing.com reports the filing of Form 144 for Monte Rosa Therapeutics on June 23. Form 144 is a notice of the intent to sell restricted securities. The brief notice also includes the stock symbol "GLUE" and its change percentage.
Form 144 MONTE ROSA THERAPEUTICS INC For: 23 June By Investing.com
This article announces the filing of Form 144 for Monte Rosa Therapeutics Inc. on June 23. It is a very brief notification from Investing.com, providing no further details about the filing itself. The article mainly consists of navigation, news headlines, market data, and promotional content from the Investing.com platform.
Form 144 MONTE ROSA THERAPEUTICS For: 23 June By Investing.com
This article from Investing.com reports the filing of Form 144 for Monte Rosa Therapeutics on June 23. Form 144 is filed with the SEC by insiders who intend to sell restricted or controlled securities. The article provides only this succinct detail without further commentary or financial analysis.
Form 144 MONTE ROSA THERAPEUTICS INC For: 23 June By Investing.com
This article announces the filing of Form 144 for MONTE ROSA THERAPEUTICS INC on June 23. It emphasizes the risks associated with trading financial instruments and cryptocurrencies, advising potential investors to be aware of market volatility and to seek professional advice. The content also notes that data provided by Investing.com is not always real-time or accurate and should be used for indicative purposes only.
GLUE (NASDAQ: GLUE) insider files Form 144 to sell 11,845 shares on 06/23/2026
An insider at Monte Rosa Therapeutics (NASDAQ: GLUE) has filed a Form 144 to sell 11,845 shares of common stock. The proposed sale, scheduled for June 23, 2026, includes 6,000 shares from stock options exercised on the same date and 5,845 shares from restricted stock units granted on January 2, 2025. The transaction will be facilitated by Morgan Stanley Smith Barney LLC on the NASDAQ market.
GLUE (NASDAQ) Rule 144 notice lists multiple dated share sales and option exercise
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) has filed a Rule 144 notice regarding proposed sales of Common shares. The filing details transactions dated May 22, 2026, May 27, 2026, and June 17, 2026, alongside a proposed exercise of stock options for cash on June 23, 2026. This notice is an administrative disclosure of intended resale of restricted shares, not an offering by the issuer, and actual transfers would be reflected in subsequent reports.
Monte Rosa Therapeutics strategy focus, shares on Nasdaq in biotech peer view
Monte Rosa Therapeutics focuses on targeted protein degradation in oncology and trades as a small-cap biotech company on the Nasdaq Global Market. The company's business model involves developing proprietary drug candidates and potentially partnering with larger pharmaceutical groups, with revenues expected from milestone payments, licensing, and product sales. Monte Rosa Therapeutics operates in the life sciences sector, focusing on biological products and early-stage oncology research, and is considered a high-volatility, small-cap biotech name with a developing pipeline and negative free cash flow due to R&D investments.
GLUE - Monte Rosa Therapeutics Inc Latest SEC Filings
This article provides detailed financial data and performance metrics for Monte Rosa Therapeutics Inc. (GLUE), including its latest stock price, market capitalization, income, sales, and various valuation ratios. It also lists key statistics such as EPS, insider and institutional ownership, profitability margins, and stock performance over different periods.
Monte Rosa (NASDAQ: GLUE) CSO sells 3,000 shares under 10b5-1 plan
Monte Rosa Therapeutics' Chief Scientific Officer, Sharon Townson, exercised options for 3,000 shares of common stock at $6.14 per share and simultaneously sold them in an open-market transaction at $19.00 per share. These transactions, totaling $57,000, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in February 2026. Following these trades, Townson directly holds 67,845 common shares and 206,290 outstanding stock options.
COO of Monte Rosa (NASDAQ: GLUE) sells 2,176 shares under 10b5-1 plan
Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics (NASDAQ: GLUE), exercised stock options for 2,176 shares at $3.98 each and subsequently sold all 2,176 shares at $19.00 each on June 17, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026. Following these transactions, she directly owns 62,371 common shares and retains 33,473 stock options.
Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by Baker BROS. Advisors LP
Baker BROS. Advisors LP reduced its stake in Monte Rosa Therapeutics (GLUE) by 11.6% in Q4, selling over 570,000 shares, though still holding 4.35 million shares valued at $68.1 million. Despite weaker-than-expected quarterly results with a loss of $0.45 per share and lower revenue, analysts generally maintain a "Moderate Buy" consensus rating with a $32.50 price target. Insider transactions also show recent share sales by key executives.
Monte Rosa Therapeutics Inc (GLUE) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Monte Rosa Therapeutics Inc (GLUE), highlighting its current earnings forecast score of 8.67, ranking 71st in the Biotechnology & Medical Research industry. Analysts have an average price target of $18.00, with a predominantly "Buy" rating based on 9 analysts. The company's expected revenue for the next quarter is $5.52M, and the EPS for the previous quarter was -$0.54 against an expectation of -$0.45, with the next quarter's EPS expected at -$0.38.
BVF Inc. IL Decreases Stock Holdings in Monte Rosa Therapeutics, Inc. $GLUE
BVF Inc. IL significantly reduced its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 32.2% in the fourth quarter, selling over 1.8 million shares. Despite this reduction, Monte Rosa Therapeutics remains BVF's 17th largest holding, and analysts maintain a "Moderate Buy" rating with a consensus price target of $32.50, even as the company recently reported a wider-than-expected loss and lower revenue. Insider selling also continued, with Philip Nickson and COO Jennifer Champoux reducing their ownership.
